

Supply of Medicine

PATIENT GROUP DIRECTION (PGD) FOR

**CLARITHROMYCIN 250MG TABLETS OR
125MG/5ML & 250MG/5ML SUSPENSION**

**YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE
YOU ATTEMPT TO WORK ACCORDING TO IT**

Clinical Condition	
Indication	For the prophylaxis against infection following animal or human bites or puncture wounds & bacterial skin infections as a result of this type of injury. This PGD is for penicillin allergic children ONLY Metronidazole is needed in addition to Clarithromycin for bites / puncture wounds
Inclusion criteria	Penicillin allergic child presenting with penetrating bites or puncture wounds or bacterial skin infection suitable for treating outside of hospital
Exclusion criteria If any of the following apply the PGD CANNOT be used and the patient must be referred to a prescriber	Superficial bites where the skin is not broken – these require local treatment only. Children under the age one year Previous true anaphylactic reaction or hypersensitivity reaction to clarithromycin or any excipient. Concomitant administration of astemizole, cisapride, pimozide, warfarin and terfenadine. A history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointe Severe hepatic failure in combination with renal impairment. Fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency Immunocompromised patients Previous course of antibiotics for the same episode.
Cautions - Seek further advice from doctor before proceeding and document advice	Severe renal impairment (although mainly excreted by liver) Concomitant hepatotoxic drugs Check current BNF for interactions if child is on any other medicines If bitten abroad and rabies is a possibility contact Health Protection Agency, CCDC or local microbiologist
Further information	For human bites consider blood borne viruses and follow trust needle stick injury policy. Check tetanus status.
Action if patient declines or is excluded	Refer to patient's GP or relevant specialist. Refer to supervising doctor/receiving facility as appropriate. Document refusal or action taken in patient's records.

Supply of Medicine

PATIENT GROUP DIRECTION (PGD) FOR




**CLARITHROMYCIN 250MG TABLETS OR
125MG/5ML & 250MG/5ML SUSPENSION**

Drug Details																									
Name, form & strength of medicine	Clarithromycin 250mg tablets; Clarithromycin 125mg/5ml or 250mg/5ml suspension 250mg/5ml oral suspension																								
Legal status	POM																								
Route/Method	Oral																								
Dosage / frequency	Dosage Based on Body Weight (kg)																								
	<table border="1"> <thead> <tr> <th>Weight* (kg)</th> <th>Approx Age (yrs)</th> <th>Dosage (ml) of 125mg/5ml susp</th> <th>Dosage per 5ml teaspoonful twice daily</th> </tr> </thead> <tbody> <tr> <td>8-11</td> <td>1 - 2</td> <td>2.5 (62.5mg)</td> <td>0.5</td> </tr> <tr> <td>12-19</td> <td>3 - 6</td> <td>5 (125mg)</td> <td>1</td> </tr> <tr> <td>20-29</td> <td>7 - 9</td> <td>7.5(187.5mg)</td> <td>1.5</td> </tr> <tr> <td>30-40</td> <td>10 - 12</td> <td>10 (250mg)</td> <td>2</td> </tr> <tr> <td>40+</td> <td>13+</td> <td>10 (250mg)</td> <td>2</td> </tr> </tbody> </table>	Weight* (kg)	Approx Age (yrs)	Dosage (ml) of 125mg/5ml susp	Dosage per 5ml teaspoonful twice daily	8-11	1 - 2	2.5 (62.5mg)	0.5	12-19	3 - 6	5 (125mg)	1	20-29	7 - 9	7.5(187.5mg)	1.5	30-40	10 - 12	10 (250mg)	2	40+	13+	10 (250mg)	2
	Weight* (kg)	Approx Age (yrs)	Dosage (ml) of 125mg/5ml susp	Dosage per 5ml teaspoonful twice daily																					
	8-11	1 - 2	2.5 (62.5mg)	0.5																					
	12-19	3 - 6	5 (125mg)	1																					
	20-29	7 - 9	7.5(187.5mg)	1.5																					
	30-40	10 - 12	10 (250mg)	2																					
40+	13+	10 (250mg)	2																						
Less than 8kg dose at 7.5mg/kg bd (use 125mg/5ml strength) All doses twice daily																									
Duration of treatment	7 days																								
Quantity to supply	Enough to complete a 7 day course (discard any remainder)																								
Side effects	Mild abdominal pain, diarrhoea, nausea, vomiting and taste perversion. If adverse effects occur the patient should consult their clinic, GP, A&E for advice.																								
Advice to patient or carer	Supply manufacturer's patient information leaflet If suspension is used shake well before dose and store in fridge Take the complete course A syringe will be needed for some patients to measure the correct dose. Warn of possible side-effects listed above If the infection appears to be spreading or getting worse in any way or if fever develops, immediate medical advice must be sought.																								

Supply of Medicine

PATIENT GROUP DIRECTION (PGD) FOR

**CLARITHROMYCIN 250MG TABLETS OR
125MG/5ML & 250MG/5ML SUSPENSION**

Staff Characteristics	
Professional qualifications	Nurses on the NMC Register
Specialist competencies or qualifications	A registered nurse, after discussion and agreement with the service/departmental lead in the MIU unit. Has undertaken training in and attended annual updates on and is therefore competent to supply and administer medicines under PGDs Is trained in the management anaphylaxis, and holds a Minor injury qualification.
Continuing education & training	It is the responsibility of the individual to keep up-to-date with clinical developments as part of their continued professional development.
Referral Arrangements and Audit Trail	
Records/audit trail	Patient's name, address, date of birth, Contact details of GP (if registered), Diagnosis, Dose and form supplied, Advice given to patient (including side effects), Signature/name of staff who supplied the medication, Details of any adverse drug reaction and actions taken including documentation in the patient's medical record, Referral arrangements (including self-care)
References/Resources and comments	Current versions of SPC – Summary of Product Characteristics BNF – British National Formulary for Children, County Antibiotics Guidance
Clinical Authorisation	
Lead Doctor	Dr John Devapriam, Medical Director Signature:  Date: 6/8/19
Lead Pharmacist	Dr Alex Johnson, Pharmacist Signature:  Date: 12/6/19
Organisational Authorisation	
On behalf of Worcestershire Health and Care NHS Trust	Michelle Clarke, Director Nursing & Quality Signature:  Date: 6/6/19
Patient Group Direction Peer Reviewed by	
Senior MIU nurses	

